Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance

Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models,...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Invest
المؤلفون الرئيسيون: Nambiar, Dhanya K., Aguilera, Todd, Cao, Hongbin, Kwok, Shirley, Kong, Christina, Bloomstein, Joshua, Wang, Zemin, Rangan, Vangipuram S., Jiang, Dadi, von Eyben, Rie, Liang, Rachel, Agarwal, Sonya, Colevas, A. Dimitrios, Korman, Alan, Allen, Clint T., Uppaluri, Ravindra, Koong, Albert C., Giaccia, Amato, Le, Quynh Thu
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Clinical Investigation 2019
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877340/
https://ncbi.nlm.nih.gov/pubmed/31710313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129025
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة